GlassScriptPhysician profile
Janice M Fordham
NPI 1609197433
$457.42
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $129.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $52.45 | 2019 | |
| Pfizer INC. | $47.71 | 2019 | |
| Merck Sharp & Dohme LLC | $43.17 | 2019 | |
| Lilly USA, LLC | $28.02 | 2019 | |
| Boston Scientific Corporation | $27.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.38 | 2019 | |
| Glaxosmithkline, LLC. | $16.20 | 2019 | |
| Sanofi Pasteur INC. | $14.76 | 2019 | |
| Novo Nordisk INC | $13.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Fordham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.